Literatur-DB: A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.
| Titel: | A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. |
| Kategorien: | Gallengangskarzinom |
| BuchID: | 90 |
| Autor: | Verschiedene |
| ISBN-10(13): | KA |
| Publikationsdatum: | 2009 03 |
| Number of pages: | 0 |
| Sprache: | Nicht spezifiziert |
| Preis: | 0.00 |
| Bewertung: |
|
| Bild: |
zum Original
|
| Beschreibung: |
AbstractPancreatic and biliary cancers are relatively resistant to chemotherapy and radiation and may therefore provide an opportunity for testing the potential of immunotherapy. MUC1 is an epithelial cell glycoprotein that is highly overexpressed and aberrantly glycosylated in many adenocarcinomas, including pancreatic tumors, providing a tumor specific antigen and target. We performed a Phase I/II clinical trial of a MUC1 peptide-loaded DC vaccine in 12 pancreatic and biliary cancer patients following resection of their primary tumors. Artikel-Nr.: 6(B):955-964 | PubMed-ID: 19129927 | DOI: | ISBN: |
Rezensionen
